Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 10, 2010, Pages 2590-2597

  Lu, Tzu Pin ^a   Tsai, Mong Hsun ^a   Lee, Jang Ming ^b   Hsu, Chung Ping ^c   Chen, Pei Chun ^a   Lin, Chung Wu ^b   Shih, Jin Yuan ^b   Yang, Pan Chyr ^b   Hsiao, Chuhsing Kate ^a   Lai, Liang Chuan ^a,b   Chuang, Eric Y ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

SEMAPHORIN; SEMAPHORIN 5A; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; NERVE FIBER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; TAIWAN;

CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77958069025     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0332     Document Type: Article

References (47)

1. Nugent WC, Edney MT, Hammerness PG, et al. Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann Thorac Surg 1997;63:193-7.
2. Wood ME, Kelly K, Mullineaux LG, Bunn PAJ. The inherited nature of lung cancer: a pilot study. Lung Cancer 2000;30:135-44.
3. Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995;141:1023-32.
4. Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988;48:7279-84.
5. Alavanja MC, Brown CC, Swanson C, Brownson RC. Saturated fat intake and lung cancer risk among nonsmoking women in Missouri. J Natl Cancer Inst 1993;85:1906-16.
6. De Stefani E, Deneo-Pellegrini H, Mendilaharsu M, Carzoglio JC, Ronco A. Dietary fat and lung cancer: a case-control study in Uruguay. Cancer Causes Control 1997;8:913-21. (Pubitemid 27485467)
7. Samet JM, Avila-Tang E, Boffetta P, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 2009;15:5626-45.
8. Ger LP, Liou SH, Shen CY, Kao SJ, Chen KT. Risk factors of lung cancer. J Formos Med Assoc 1992;91 Suppl 3:S222-31.
9. Hirayasu T, Iwamasa T, Kamada Y, et al. Human papillomavirus DNA in squamous cell carcinoma of the lung. J Clin Pathol 1996;49:810-7.
10. Hainaut P, Pfeifer GP. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22:367-74.
11. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003;21:229-39.
12. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
13. Martin P, Kelly CM, Carney D. Epidermal growth factor receptor-targeted agents for lung cancer. Cancer Control 2006;13:129-40. (Pubitemid 43911188)
14. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
15. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-21.
16. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-33.
17. Chen CJ, Wu HY, Chuang YC, et al. Epidemiologic characteristics and multiple risk factors of lung cancer in Taiwan. Anticancer Res 1990;10:971-6.
18. Yang SP, Luh KT, Kuo SH, Lin CC. Chronological observation of epidemiological characteristics of lung cancer in Taiwan with etiological consideration - a 30-year consecutive study. Jpn J Clin Oncol 1984;14:7-19.
19. Potiron VA, Roche J, Drabkin HA. Semaphorins and their receptors in lung cancer. Cancer Lett 2008;273:1-14.
20. Chedotal A, Kerjan G, Moreau-Fauvarque C. The brain within the tumor: new roles for axon guidance molecules in cancers. Cell Death Differ 2005;12:1044-56.
21. Kruger RP, Aurandt J, Guan KL. Semaphorins command cells to move. Nat Rev Mol Cell Biol 2005;6:789-800.
22. Nagai H, Sugito N, Matsubara H, et al. CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells. Oncogene 2007;26:4025-31.
23. Nasarre P, Kusy S, Constantin B, et al. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 2005;7:180-9.
24. Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A 2004;101:11432-7.
25. Tomizawa Y, Sekido Y, Kondo M, et al. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A 2001;98:13954-9.
26. Brambilla E, Constantin B, Drabkin H, Roche J. Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am J Pathol 2000;156:939-50.
27. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18:207-8.
28. Su LJ, Chang CW, Wu YC, et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 2007;8:140.
29. Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 2008;3:e1651.
30. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-10.
31. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat Genet 2003;34:267-73.
32. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
33. Tian L, Greenberg SA, Kong SW, et al. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A 2005;102:13544-9.
34. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
35. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
36. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008;41:278-86.
37. Rudin CM, Avila-Tang E, Harris CC, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009;15:5646-61.
38. Neufeld G, Shraga-Heled N, Lange T, et al. Semaphorins in cancer. Front Biosci 2005;10:751-60.
39. Zhou Y, Gunput RA, Pasterkamp RJ. Semaphorin signaling: progress made and promises ahead. Trends Biochem Sci 2008;33:161-70.
40. Rizzolio S, Tamagnone L. Semaphorin signals on the road to cancer invasion and metastasis. Cell Adh Migr 2007;1:62-8.
41. Kusy S, Nasarre P, Chan D, et al. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia 2005;7:457-65.
42. Sadanandam A, Rosenbaugh EG, Singh S, Varney M, Singh RK. Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis. Microvasc Res 2009;79:1-9.
43. Fiore R, Rahim B, Christoffels VM, Moorman AF, Puschel AW. Inactivation of the SEMA5A gene results in embryonic lethality and defective remodeling of the cranial vascular system. Mol Cell Biol 2005;25:2310-9. (Pubitemid 40354627)
44. Sadanandam A, Varney ML, Kinarsky L, et al. Identification of functional cell adhesion molecules with a potential role in metastasis by a combination of in vivo phage display and in silico analysis. OMICS 2007;11:41-57.
45. Pan GQ, Ren HZ, Zhang SF, Wang XM, Wen JF. Expression of semaphorin 5A and its receptor plexin B3 contributes to invasion and metastasis of gastric carcinoma. World J Gastroenterol 2009;15:2800-4.
46. Artigiani S, Conrotto P, Fazzari P, et al. Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep 2004;5:710-4.
47. Rudin CM, Avila-Tang E, Samet JM. Lung cancer in never smokers: a call to action. Clin Cancer Res 2009;15:5622-5.